查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1980182

生物製藥CMO市場規模、佔有率、成長及全球產業分析：按類型、應用和地區的洞察，2026-2034年預測

Biopharmaceutical CMO Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 155 Pages | 商品交期: 請詢問到貨日

價格

生物製藥合約製造（CMO）市場的成長要素

2025年全球生物製藥合約製造組織（CMO）市場規模為190億美元，預計2026年將達到217.4億美元，最終在2034年成長至703.6億美元，預測期內年複合成長率（CAGR）為15.81%。北美地區在2025年佔據市場主導地位，市場佔有率達39.70%。這主要歸功於北美地區擁有大量的生產設施以及主要市場參與者的策略性業務擴張措施。

生物製藥合約製造機構（CMO）在藥物研發、生產、分析測試和包裝等領域提供專業服務。透過外包這些流程，生物製藥公司可以專注於研發和行銷等核心業務，同時將大規模生產委託給 CMO。生物製藥、生物相似藥和複雜治療方法的興起，以及技術的進步和日益嚴格的監管要求，顯著提升了對 CMO 的需求。

市場促進因素

市場成長的主要驅動力是生物製藥和生物相似藥需求的不斷成長。隨著生物製藥從小分子藥物向大分子藥物的轉變，以及生物製藥核准數量的增加，合約製造組織（CMO）在生產過程中變得不可或缺。例如，美國FDA在2023年核准了55種新藥（其中18種為生物製藥），凸顯了外包需求的成長。

其他關鍵因素包括成本和時間效率。透過與合約製造組織（CMO）合作，無需進行大量資本投資即可利用先進的設備和熟練的人員。此外，個人化醫療和標靶治療（尤其是在腫瘤領域）的進步也推動了對合約製造服務的需求。

市場限制因素

高昂的營運和基礎設施成本限制了市場成長。建立大規模生產設施，特別是不銹鋼生物生產工廠，需要大量資金。此外，嚴格遵守cGMP法規以及原料供應鏈的脆弱性也對高效生產構成挑戰。

市場機會

一次性生物製程技術的應用帶來了盈利的成長機會。一次性生物反應器（SUB）和一次性混合器具有柔軟性、交叉污染風險低、前置作業時間短等優點。新興市場產能的擴張也為合約製造商（CMO）提供了抓住潛在市場需求的機會。

市場趨勢

關鍵趨勢包括連續生產（將端到端生產流程整合以提高效率）以及日益重視數位化和人工智慧整合以最佳化流程。合約製造機構（CMO）和生物製藥公司之間的策略合作夥伴關係日益增多，能夠進行聯合投資、共用專業知識並提升產能。

新冠疫情的影響

疫情期間，由於對新冠疫苗合約製造的需求激增，市場受到了積極影響。多家合約製造商與疫苗研發公司簽訂合約，生產已通過核准的疫苗和臨床候選疫苗。然而，隨著對新冠相關產品的需求下降，2023-2024年市場成長趨於正常。

市場區隔

依服務：

  • 到2026年，製造服務將成為市場主導力量，佔據45.53%的市場佔有率，這主要得益於合約製造計劃的成長。下游製程由於其複雜的技術要求，仍將保持最大的市場佔有率。
  • 灌裝和表面處理工程、分析和品管（QC）測試以及包裝也在不斷發展，這得益於產品核准和生物製藥產品上市數量的增加。

依原料分類：

  • 到2026年，哺乳動物表達系統將佔據主導地位，市場佔有率高達71.16%，這主要得益於其在生物製藥生產中的廣泛應用。非哺乳動物表達系統也在成長，尤其是在微生物衍生產品領域。

依產品：

  • 到2026年，生物製藥將引領市場，佔據 93.18%的市場佔有率，這主要得益於產品核可的增加和開發平臺的擴大。
  • 預計生物相似藥將實現強勁成長，尤其是在對成本敏感的市場。

區域趨勢

  • 北美：預計到2025年市場規模將達到 75.3億美元，到2026年將達到 86.3億美元，其中美國在2026年將以 79.1億美元的主導，這得益於新技術的採用和產能的擴張。
  • 歐洲：預計到2026年，英國將達到 15.1億美元，德國將達到 17.5億美元，佔世界 CMO 生產能力的37%。
  • 亞太地區：受境外外包的推動，該地區預計將經歷最快的成長。到2026年，日本預計將達到6.2億美元，中國將達到12.2億美元，印度將達到7.5億美元。
  • 拉丁美洲、中東和非洲：儘管市場規模較小，但隨著基礎設施的改善，市場普及速度預計將會加快。

主要企業及產業趨勢

主要企業包括Lonza、Samsung Biologics、WuXi Biologics、Catalent Inc.、FUJIFILM Diosynth Biotechnologies、Siegfried Holding AG、Recipharm AB、Cambrex、Thermo Fisher Scientific。策略合作和投資推動成長：

  • 2024年 12月：AGC Biologics 的米蘭細胞和基因治療設施獲得美國 FDA核准，可進行 AUCATZYL 的商業化生產。
  • 2024年 11月：三星生物製劑與歐洲簽署了一項生產協議，有效期至2031年。
  • 2024年 10月：與 Lonza 公司建立了合作關係，進行 ADC 的商業化生產。
  • 2024年 7月：Siegfried Holding 收購了美國一家早期 CDMO 公司。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 生物製藥合約製造組織（CMO）的技術進步
  • 主要產業趨勢（合併、收購、合作等）
  • 概述：主要國家和地區的監管狀況
  • 新冠疫情對市場的影響

第5章 2021-2034年全球生物製藥CMO市場分析、洞察與預測

  • 市場分析、洞察與預測：依服務分類
    • 製造業
      • 上游工程
      • 下游工程
    • 填充和表面處理工程
    • 分析和品管（QC）測試
    • 包裝
  • 市場分析、洞察與預測：依來源
    • 哺乳動物
    • 非哺乳動物
  • 市場分析、洞察與預測：依產品分類
    • 生物製劑
    • 生物相似藥
  • 市場分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美生物製藥CMO市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲生物製藥CMO市場分析、洞察與預測（2021-2034年）

  • 國家
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太地區生物製藥CMO市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章 拉丁美洲生物製藥CMO市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 中東和非洲生物製藥CMO市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Thermo Fisher Scientific Inc.
    • Wuxi Biologics
    • Lonza
    • Recipharm AB
    • Catalent Inc.
    • FUJIFILM Corporation（FUJIFILM Diosynth Biotechnologies）
    • Cambrex Corporation
    • Samsung Biologics
    • Siegfried Holding AG
Product Code: FBI103346

Growth Factors of biopharmaceutical Contract Manufacturing Organization (CMO) Market

The global biopharmaceutical Contract Manufacturing Organization (CMO) market was valued at USD 19.00 billion in 2025 and is projected to reach USD 21.74 billion in 2026, ultimately growing to USD 70.36 billion by 2034, exhibiting a CAGR of 15.81% during the forecast period. North America dominated the market in 2025 with a 39.70% share, attributed to the high number of manufacturing facilities and strategic expansion initiatives by key market players.

Biopharmaceutical CMOs provide specialized services including drug development, manufacturing, analytical testing, and packaging. Outsourcing these processes allows biopharmaceutical companies to focus on core competencies such as research, development, and marketing while relying on CMOs for large-scale manufacturing. The demand for CMOs has grown significantly due to the rise of biologics, biosimilars, and complex therapies, along with technological advancements and stringent regulatory requirements.

Market Drivers

The primary driver of market growth is the rising demand for biologics and biosimilars. The shift from small-molecule drugs to large-molecule biopharmaceuticals, coupled with the increasing number of biologics approvals, has made CMOs essential for production. For example, in 2023, the U.S. FDA approved 55 new drug products, including 18 biologics, highlighting the increasing outsourcing needs.

Other key drivers include cost and time efficiency, as CMOs offer access to advanced equipment and skilled labor without significant capital investment. The growth of personalized medicine and targeted therapies, particularly in oncology, also fuels the demand for contract manufacturing services.

Market Restraints

High operational and infrastructure costs limit market growth. Establishing large-scale manufacturing facilities, especially stainless steel bioproduction plants, requires significant capital. Additionally, stringent regulatory compliance under cGMP regulations and supply chain vulnerabilities for raw materials pose challenges to efficient manufacturing.

Market Opportunities

The adoption of single-use bioprocessing technologies offers lucrative growth opportunities. Single-Use Bioreactors (SUBs) and disposable mixers provide flexibility, reduced cross-contamination risks, and faster turnaround times. Expanding manufacturing capabilities in emerging markets also presents opportunities for CMOs to capture untapped demand.

Market Trends

Key trends include continuous manufacturing, which integrates end-to-end production for increased efficiency, and the growing emphasis on digitalization and AI integration for process optimization. Strategic collaborations between CMOs and biopharmaceutical companies are rising, enabling co-investments, shared expertise, and enhanced production capabilities.

COVID-19 Impact

The pandemic positively influenced the market due to the surge in demand for contract manufacturing of COVID-19 vaccines. Several CMOs signed agreements with vaccine developers to produce both approved vaccines and clinical candidates. However, 2023-2024 saw a normalization in growth as COVID-19-related production demand declined.

Market Segmentation

By Service:

  • Manufacturing services dominated in 2026 with 45.53% share, driven by the increasing number of contract manufacturing projects. Downstream processing held the largest share due to its complex technology requirements.
  • Fill & finish operations, analytical & QC studies, and packaging are also growing, driven by product approvals and increased biologics launches.

By Source:

  • Mammalian expression systems led with 71.16% share in 2026, due to their widespread use in biologics production. Non-mammalian systems are also growing, especially for microbial-based products.

By Product:

  • Biologics dominated in 2026 with 93.18% share, fueled by increasing product approvals and a growing development pipeline.
  • Biosimilars are projected to witness strong growth, particularly in cost-sensitive markets.

Regional Insights

  • North America: Market size USD 7.53 billion in 2025 and USD 8.63 billion in 2026, led by the U.S. with USD 7.91 billion in 2026, supported by technology adoption and capacity expansion.
  • Europe: Market projected to reach UK USD 1.51 billion and Germany USD 1.75 billion in 2026, with 37% of global CMO capacity.
  • Asia Pacific: Fastest growth, driven by offshoring trends. Japan USD 0.62 billion, China USD 1.22 billion, India USD 0.75 billion in 2026.
  • Latin America & Middle East/Africa: Smaller markets, but improving infrastructure is expected to boost adoption.

Key Players & Industry Developments

Prominent players include Lonza, Samsung Biologics, WuXi Biologics, Catalent Inc., FUJIFILM Diosynth Biotechnologies, Siegfried Holding AG, Recipharm AB, Cambrex, and Thermo Fisher Scientific. Strategic collaborations and investments are driving growth:

  • Dec 2024: AGC Biologics' Milan Cell and Gene site approved by U.S. FDA for commercial manufacturing of AUCATZYL.
  • Nov 2024: Samsung Biologics signed a Europe-based manufacturing agreement through 2031.
  • Oct 2024: Lonza collaborated for commercial-scale manufacturing of ADCs.
  • July 2024: Siegfried Holding acquired an early-phase CDMO in the U.S.

Conclusion

The biopharmaceutical CMO market is expected to expand from USD 19.00 billion in 2025 to USD 70.36 billion by 2034, at a CAGR of 15.81%, driven by increasing biologics approvals, rising outsourcing trends, adoption of advanced manufacturing technologies, and expansion into emerging markets. While high operational costs and regulatory challenges remain, continuous innovation, strategic partnerships, and digitalization will ensure robust growth across the forecast period.

Segmentation By Service

  • Manufacturing
    • Upstream Processing
    • Downstream Processing
  • Fill & Finish Operations
  • Analytical & QC Studies
  • Packaging

By Source

  • Mammalian
  • Non-mammalian

By Product

  • Biologics
  • Biosimilars

By Region

  • North America (By Service, Source, Product, and Country)
    • U.S.
    • Canada
  • Europe (By Service, Source, Product, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Service, Source, Product, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Latin America (By Service, Source, Product, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Service, Source, Product, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Technological Advancements in Biopharmaceutical CMO
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Overview: Regulatory Scenario, By Key Countries/Regions
  • 4.4. Impact of COVID 19 on the Market

5. Global Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Service
    • 5.1.1. Manufacturing
      • 5.1.1.1. Upstream Processing
      • 5.1.1.2. Downstream Processing
    • 5.1.2. Fill & Finish Operations
    • 5.1.3. Analytical & QC Studies
    • 5.1.4. Packaging
  • 5.2. Market Analysis, Insights and Forecast - By Source
    • 5.2.1. Mammalian
    • 5.2.2. Non-Mammalian
  • 5.3. Market Analysis, Insights and Forecast - By Product
    • 5.3.1. Biologics
    • 5.3.2. Biosimilars
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Service
    • 6.1.1. Manufacturing
      • 6.1.1.1. Upstream Processing
      • 6.1.1.2. Downstream Processing
    • 6.1.2. Fill & Finish Operations
    • 6.1.3. Analytical & QC Studies
    • 6.1.4. Packaging
  • 6.2. Market Analysis, Insights and Forecast - By Source
    • 6.2.1. Mammalian
    • 6.2.2. Non-Mammalian
  • 6.3. Market Analysis, Insights and Forecast - By Product
    • 6.3.1. Biologics
    • 6.3.2. Biosimilars
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Service
    • 7.1.1. Manufacturing
      • 7.1.1.1. Upstream Processing
      • 7.1.1.2. Downstream Processing
    • 7.1.2. Fill & Finish Operations
    • 7.1.3. Analytical & QC Studies
    • 7.1.4. Packaging
  • 7.2. Market Analysis, Insights and Forecast - By Source
    • 7.2.1. Mammalian
    • 7.2.2. Non-Mammalian
  • 7.3. Market Analysis, Insights and Forecast - By Product
    • 7.3.1. Biologics
    • 7.3.2. Biosimilars
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. U.K.
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Service
    • 8.1.1. Manufacturing
      • 8.1.1.1. Upstream Processing
      • 8.1.1.2. Downstream Processing
    • 8.1.2. Fill & Finish Operations
    • 8.1.3. Analytical & QC Studies
    • 8.1.4. Packaging
  • 8.2. Market Analysis, Insights and Forecast - By Source
    • 8.2.1. Mammalian
    • 8.2.2. Non-Mammalian
  • 8.3. Market Analysis, Insights and Forecast - By Product
    • 8.3.1. Biologics
    • 8.3.2. Biosimilars
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. China
    • 8.4.2. India
    • 8.4.3. Japan
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Service
    • 9.1.1. Manufacturing
      • 9.1.1.1. Upstream Processing
      • 9.1.1.2. Downstream Processing
    • 9.1.2. Fill & Finish Operations
    • 9.1.3. Analytical & QC Studies
    • 9.1.4. Packaging
  • 9.2. Market Analysis, Insights and Forecast - By Source
    • 9.2.1. Mammalian
    • 9.2.2. Non-Mammalian
  • 9.3. Market Analysis, Insights and Forecast - By Product
    • 9.3.1. Biologics
    • 9.3.2. Biosimilars
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Biopharmaceutical CMO Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Service
    • 10.1.1. Manufacturing
      • 10.1.1.1. Upstream Processing
      • 10.1.1.2. Downstream Processing
    • 10.1.2. Fill & Finish Operations
    • 10.1.3. Analytical & QC Studies
    • 10.1.4. Packaging
  • 10.2. Market Analysis, Insights and Forecast - By Source
    • 10.2.1. Mammalian
    • 10.2.2. Non-Mammalian
  • 10.3. Market Analysis, Insights and Forecast - By Product
    • 10.3.1. Biologics
    • 10.3.2. Biosimilars
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Thermo Fisher Scientific Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Wuxi Biologics
      • 11.2.2.1. Overview
      • 11.2.2.2. Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Lonza
      • 11.2.3.1. Overview
      • 11.2.3.2. Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Recipharm AB
      • 11.2.4.1. Overview
      • 11.2.4.2. Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Catalent Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. FUJIFILM Corporation (FUJIFILM Diosynth Biotechnologies)
      • 11.2.6.1. Overview
      • 11.2.6.2. Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Cambrex Corporation
      • 11.2.7.1. Overview
      • 11.2.7.2. Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Samsung Biologics
      • 11.2.8.1. Overview
      • 11.2.8.2. Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Siegfried Holding AG
      • 11.2.9.1. Overview
      • 11.2.9.2. Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 2: Global Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Manufacturing Service, 2021-2034
  • Table 3: Global Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 4: Global Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 5: Global Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 7: North America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Manufacturing Service, 2021-2034
  • Table 8: North America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 9: North America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 10: North America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 12: Europe Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Manufacturing Service, 2021-2034
  • Table 13: Europe Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 14: Europe Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 15: Europe Biopharmaceutical CMO Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 17: Asia Pacific Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Manufacturing Service, 2021-2034
  • Table 18: Asia Pacific Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 19: Asia Pacific Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 20: Asia Pacific Biopharmaceutical CMO Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 22: Latin America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Manufacturing Service, 2021-2034
  • Table 23: Latin America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 24: Latin America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 25: Latin America Biopharmaceutical CMO Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Service, 2021-2034
  • Table 27: Middle East & Africa Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Manufacturing Service, 2021-2034
  • Table 28: Middle East & Africa Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Source, 2021-2034
  • Table 29: Middle East & Africa Biopharmaceutical CMO Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 30: Middle East & Africa Biopharmaceutical CMO Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Biopharmaceutical CMO Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Biopharmaceutical CMO Market Value Share (%), by Service, 2025 & 2034
  • Figure 3: Global Biopharmaceutical CMO Market Value Share (%), by Source, 2025 & 2034
  • Figure 4: Global Biopharmaceutical CMO Market Value Share (%), by Product, 2025 & 2034
  • Figure 5: Global Biopharmaceutical CMO Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Biopharmaceutical CMO Market Value (USD billion), by Service, 2025 & 2034
  • Figure 7: North America Biopharmaceutical CMO Market Value Share (%), by Service, 2025
  • Figure 8: North America Biopharmaceutical CMO Market Value (USD billion), by Source, 2025 & 2034
  • Figure 9: North America Biopharmaceutical CMO Market Value Share (%), by Source, 2025
  • Figure 10: North America Biopharmaceutical CMO Market Value (USD billion), by Product, 2025 & 2034
  • Figure 11: North America Biopharmaceutical CMO Market Value Share (%), by Product, 2025
  • Figure 12: North America Biopharmaceutical CMO Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Biopharmaceutical CMO Market Value Share (%), By Country, 2025
  • Figure 14: Europe Biopharmaceutical CMO Market Value (USD billion), by Service, 2025 & 2034
  • Figure 15: Europe Biopharmaceutical CMO Market Value Share (%), by Service, 2025
  • Figure 16: Europe Biopharmaceutical CMO Market Value (USD billion), by Source, 2025 & 2034
  • Figure 17: Europe Biopharmaceutical CMO Market Value Share (%), by Source, 2025
  • Figure 18: Europe Biopharmaceutical CMO Market Value (USD billion), by Product, 2025 & 2034
  • Figure 19: Europe Biopharmaceutical CMO Market Value Share (%), by Product, 2025
  • Figure 20: Europe Biopharmaceutical CMO Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Biopharmaceutical CMO Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Biopharmaceutical CMO Market Value (USD billion), by Service, 2025 & 2034
  • Figure 23: Asia Pacific Biopharmaceutical CMO Market Value Share (%), by Service, 2025
  • Figure 24: Asia Pacific Biopharmaceutical CMO Market Value (USD billion), by Source, 2025 & 2034
  • Figure 25: Asia Pacific Biopharmaceutical CMO Market Value Share (%), by Source, 2025
  • Figure 26: Asia Pacific Biopharmaceutical CMO Market Value (USD billion), by Product, 2025 & 2034
  • Figure 27: Asia Pacific Biopharmaceutical CMO Market Value Share (%), by Product, 2025
  • Figure 28: Asia Pacific Biopharmaceutical CMO Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Biopharmaceutical CMO Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Biopharmaceutical CMO Market Value (USD billion), by Service, 2025 & 2034
  • Figure 31: Latin America Biopharmaceutical CMO Market Value Share (%), by Service, 2025
  • Figure 32: Latin America Biopharmaceutical CMO Market Value (USD billion), by Source, 2025 & 2034
  • Figure 33: Latin America Biopharmaceutical CMO Market Value Share (%), by Source, 2025
  • Figure 34: Latin America Biopharmaceutical CMO Market Value (USD billion), by Product, 2025 & 2034
  • Figure 35: Latin America Biopharmaceutical CMO Market Value Share (%), by Product, 2025
  • Figure 36: Latin America Biopharmaceutical CMO Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Biopharmaceutical CMO Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Biopharmaceutical CMO Market Value (USD billion), by Service, 2025 & 2034
  • Figure 39: Middle East & Africa Biopharmaceutical CMO Market Value Share (%), by Service, 2025
  • Figure 40: Middle East & Africa Biopharmaceutical CMO Market Value (USD billion), by Source, 2025 & 2034
  • Figure 41: Middle East & Africa Biopharmaceutical CMO Market Value Share (%), by Source, 2025
  • Figure 42: Middle East & Africa Biopharmaceutical CMO Market Value (USD billion), by Product, 2025 & 2034
  • Figure 43: Middle East & Africa Biopharmaceutical CMO Market Value Share (%), by Product, 2025
  • Figure 44: Middle East & Africa Biopharmaceutical CMO Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Biopharmaceutical CMO Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Biopharmaceutical CMO Market Share (%), By Company, 2025